title: Ifosfamide, Cisplatin or Carboplatin, and Etoposide (ICE)-based Chemotherapy for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Lymphomas.
abstract: BACKGROUND
  High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a promising approach for lymphomas. This study aimed to evaluate the effect of ifosfamide, cisplatin or carboplatin, and etoposide (ICE)-based regimen as a mobilization regimen on relapsed, refractory, or high-risk aggressive lymphoma.
  
  
  METHODS
  From June 2001 to May 2013, patients with lymphomas who mobilized by ICE-based regimen for ASCT were analyzed in this retrospective study. The results of the autologous peripheral blood stem cells collection, toxicity, engraftment after ICE-based mobilization regimen were analyzed in this study. Furthermore, risk factors for overall survival (OS) and progression free survival (PFS) were evaluated by univariate analysis.
  
  
  RESULTS
  The stem cells were mobilized using ICE-based regimen plus rituximab or ICE-based regimen alone in 12 patients and 54 patients, respectively. The results of stem cell mobilization were excellent. Ninety-seven percentages of the patients had the stem cell collection of at least 2.0 × 10 6 CD34 + cells/kg and 68% had at least 5 × 10 6 CD34 + cells/kg. Fifty-eight percentage of the patients experienced Grade 4 neutropenia, 20% developed febrile neutropenia, and only 12% had Grade 4 thrombocytopenia. At a median follow-up of 63.8 months, the 5-year PFS and OS were 64.4% and 75.3%, respectively.
  
  
  CONCLUSIONS
  ICE is a powerful regimen for stem cell mobilization in patients with lymphomas.
authors.forename: Ping
authors.initials: P
authors.lastname: Zhou
authors.forename: Peng
authors.initials: P
authors.lastname: Liu
authors.forename: Sheng-Yu
authors.initials: SY
authors.lastname: Zhou
authors.forename: Xiao-Hui
authors.initials: XH
authors.lastname: He
authors.forename: Xiao-Hong
authors.initials: XH
authors.lastname: Han
authors.forename: Yan
authors.initials: Y
authors.lastname: Qin
authors.forename: Sheng
authors.initials: S
authors.lastname: Yang
authors.forename: Chang-Gong
authors.initials: CG
authors.lastname: Zhang
authors.forename: Lin
authors.initials: L
authors.lastname: Gui
authors.forename: Jia-Rui
authors.initials: JR
authors.lastname: Yao
authors.forename: Li-Ya
authors.initials: LY
authors.lastname: Zhao
authors.forename: Shu-Xiang
authors.initials: SX
authors.lastname: Zhang
authors.forename: Yan
authors.initials: Y
authors.lastname: Sun
authors.affiliation: Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing 100021, China.
authors.forename: Yuan-Kai
authors.initials: YK
authors.lastname: Shi
mesh_terms: D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016190:Carboplatin / Q000627:therapeutic use*; D002648:Child; D002945:Cisplatin / Q000627:therapeutic use*; D005047:Etoposide / Q000627:therapeutic use*; D005260:Female; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D006801:Humans; D007069:Ifosfamide / Q000627:therapeutic use*; D008223:Lymphoma / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D033581:Stem Cell Transplantation / Q000379:methods*; D014182:Transplantation, Autologous; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D005047:Etoposide; D016190:Carboplatin; D002945:Cisplatin; D007069:Ifosfamide